|
|
|
 |
|
|
 |
|
|
| |
 |
| |
 |
| |
| |
 |
| Santhera Pharmaceuticals AG (SANN) |
OBP III |
(Formerly Graffinity Pharmaceuticals AG; merged with MyoContract AG to form new company, Santhera Pharmaceuticals AG)
Liestal (Basel), Switzerland and Heidelberg, Germany
www.santhera.com
Santhera focuses on the discovery, development and commercialization of small molecule drugs in the areas of neuromuscular and metabolic diseases.
|
|
| |
|
|
|
|
|
